Clinical Trial

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

Name: Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis — clinical trial record (NCT06569472)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Phase I clinical trial to evaluate the efficacy and safety of CD19-targeted CAR-T in the treatment of refractory juvenile dermatomyositis (RJDM).The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).

Trial Details

NCT Number	NCT06569472
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	Juvenile Dermatomyositis
Enrollment	10 participants
Start Date	2024-07-02
Primary Completion	2027-07-31 (estimated)
Study Completion	2028-07-31 (estimated)
Updated on ClinicalTrials.gov	2024-08-26